Electronic Journal of Liver Tumor ›› 2021, Vol. 8 ›› Issue (3): 35-40.
• Review • Previous Articles Next Articles
Cao Yin, Wang Zhongxia, Jiang Chunping
Received:
2021-05-21
Online:
2021-09-30
Published:
2021-10-20
Cao Yin, Wang Zhongxia, Jiang Chunping. The prognostic value of simple inflammation-related indexes in predicting liver transplantation for hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2021, 8(3): 35-40.
[1] SCHWARTZ M E, D'AMICO F, VITALE A, et al. Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid?[J]. Eur J Surg Oncol, 2008, 34(3): 256-262. [2] JONAS S, BECHSTEIN W O, STEINMÜLLER T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis[J]. Hepatology, 2001, 33(5): 1080-1086. [3] MA Q, LIU W, JIA R, et al.Inflammation-based prognostic system predicts postoperative survival of esophageal carcinoma patients with normal preoperative serum carcinoembryonic antigen and squamous cell carcinoma antigen levels[J]. World J Surg Oncol, 2016, 14: 141. [4] WU X S, SHI L B, LI M L, et al.Evaluation of two inflammation-based prognostic scores in patients with resectable gallbladder carcinoma[J]. Ann Surg Oncol, 2014, 21(2): 449-457. [5] AGOPIAN V G, PETROWSKY H, KALDAS F M, et al.The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center[J]. Ann Surg, 2013, 258(3): 409-421. [6] LU D S, YU N C, RAMAN S S, et al.Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation[J]. Hepatology, 2005, 41(5): 1130-1137. [7] BISHAYEE A.The role of inflammation and liver cancer[J]. Adv Exp Med Biol, 2014, 816: 401-435. [8] LEE F Y, LEE S D, TSAI Y T, et al.Serum C-reactive protein as a serum marker for the diagnosis of hepatocellular carcinoma[J]. Cancer, 1989, 63(8): 1567-1571. [9] GOMEZ D, FARID S, MALIK H Z, et al.Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma[J]. World J Surg, 2008, 32(8): 1757-1762. [10] WANG Y, ATTAR B M, FUENTES H E, et al.Evaluation of the prognostic value of platelet to lymphocyte ratio in patients with hepatocellular carcinoma[J]. J Gastrointest Oncol, 2017, 8(6): 1065-1071. [11] XU Z G, YE C J, LIU L X, et al.The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: a systematic review and meta-analysis[J]. Biomark Med, 2018, 12(2): 189-199. [12] PROCTOR M J, MORRISON D S, TALWAR D, et al.A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study[J]. Eur J Cancer, 2011, 47(17): 2633-2641. [13] NAJJAR M, AGRAWAL S, EMOND J C, et al.Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2018, 5: 17-28. [14] PARISI I, TSOCHATZIS E, WIJEWANTHA H, et al.Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria[J]. Liver Transpl, 2014, 20(11): 1327-1335. [15] LAI Q, CASTRO SANTA E, RICO JURI J M, et al. Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer[J]. Transpl Int, 2014, 27(1): 32-41. [16] ISMAEL M N, FORDE J, MILLA E, et al.Utility of Inflammatory Markers in Predicting Hepatocellular Carcinoma Survival after Liver Transplantation[J]. Biomed Res Int, 2019, 2019: 7284040. [17] HALAZUN K J, HARDY M A, RANA A A, et al.Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma[J]. Ann Surg, 2009, 250(1): 141-151. [18] BERTUZZO V R, CESCON M, RAVAIOLI M, et al.Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers[J]. Transplantation, 2011, 91(11): 1279-1285. [19] WANG G Y, YANG Y, LI H, et al.A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation[J]. PLoS One, 2011, 6(9): e25295. [20] MOTOMURA T, SHIRABE K, MANO Y, et al.Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment[J]. J Hepatol, 2013, 58(1): 58-64. [21] LIMAYE A R, CLARK V, SOLDEVILA-PICO C, et al.Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma[J]. Hepatol Res, 2013, 43(7): 757-764. [22] XIAO G Q, LIU C, LIU D L, et al.Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation[J]. World J Gastroenterol, 2013, 19(45): 8398-8407. [23] YOSHIZUMI T, IKEGAMI T, YOSHIYA S, et al.Impact of tumor size, number of tumors and neutrophil-to-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma[J]. Hepatol Res, 2013, 43(7): 709-716. [24] NA G H, KIM D G, HAN J H, et al.Inflammatory markers as selection criteria of hepatocellular carcinoma in living-donor liver transplantation[J]. World J Gastroenterol, 2014, 20(21): 6594-6601. [25] SHINDOH J, SUGAWARA Y, NAGATA R, et al.Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma[J]. Transpl Int, 2014, 27(4): 391-398. [26] AGOPIAN V G, HARLANDER-LOCKE M, ZARRINPAR A, et al.A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients[J]. J Am Coll Surg, 2015, 220(4): 416-427. [27] WANG W, YE Y, WANG T, et al.Prognostic prediction of male recipients selected for liver transplantation: With special attention to neutrophil to lymphocyte ratio[J]. Hepatol Res, 2016, 46(9): 899-907. [28] HARIMOTO N, YOSHIZUMI T, SHIMAGAKI T, et al.Inflammation-based Prognostic Score in Patients with Living Donor Liver Transplantation for Hepatocellular Carcinoma[J]. Anticancer Res, 2016, 36(10): 5537-5542. [29] REN A, LI Z, ZHANG X, et al.Inflammation-Based Prognostic Scores in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma After Liver Transplantation[J]. J Hepatocell Carcinoma, 2020, 7: 101-106. [30] KONG W, QU E, SHENG N, et al.Prognostic significance of inflammation-based score in patients with hepatocellular carcinoma after liver transplantation[J]. Eur J Gastroenterol Hepatol, 2021. [31] SVENNEVIG J L, LUNDE O C, HOLTER J, et al.Lymphoid infiltration and prognosis in colorectal carcinoma[J]. Br J Cancer, 1984, 49(3): 375-377. [32] MANO Y, SHIRABE K, YAMASHITA Y, et al.Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis[J]. Ann Surg, 2013, 258(2): 301-305. [33] POON R T, FAN S T, LO C M, et al.Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation[J]. Ann Surg, 2002, 235(3): 373-382. [34] SCHREIBER R D, OLD L J, SMYTH M J.Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion[J]. Science, 2011, 331(6024): 1565-1570. [35] ZHOU D, LIANG J, XU L I, et al.Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization[J]. Oncol Lett, 2016, 11(5): 2987-2994. [36] XIA W, KE Q, WANG Y, et al.Predictive value of pre-transplant platelet to lymphocyte ratio for hepatocellular carcinoma recurrence after liver transplantation[J]. World J Surg Oncol, 2015, 13: 60. [37] PRAVISANI R, MOCCHEGIANI F, ISOLA M, et al.Postoperative Trends and Prognostic Values of Inflammatory and Nutritional Biomarkers after Liver Transplantation for Hepatocellular Carcinoma[J]. Cancers (Basel), 2021, 13(3). [38] FU H, ZHENG J, CAI J, et al.Systemic Immune-Inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients After Liver Transplantation for Hepatocellular Carcinoma within Hangzhou Criteria[J]. Cell Physiol Biochem, 2018, 47(1): 293-301. [39] LAI Q, MELANDRO F, LARGHI LAUREIRO Z, et al.Platelet-to-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer: A systematic review and meta-analysis[J]. World J Gastroenterol, 2018, 24(15): 1658-1665. [40] XIA W, KE Q, GUO H, et al.Expansion of the Milan criteria without any sacrifice: combination of the Hangzhou criteria with the pre-transplant platelet-to-lymphocyte ratio[J]. BMC Cancer, 2017, 17(1): 14. [41] CHAN J C, CHAN D L, DIAKOS C I, et al.The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer[J]. Ann Surg, 2017, 265(3): 539-546. [42] XUE P, HANG J, HUANG W, et al.Validation of Lymphocyte-to-Monocyte Ratio as a Prognostic Factor in Advanced Pancreatic Cancer: An East Asian Cohort Study of 2 Countries[J]. Pancreas, 2017, 46(8): 1011-1017. [43] MANO Y, YOSHIZUMI T, YUGAWA K, et al.Lymphocyte-to-Monocyte Ratio Is a Predictor of Survival After Liver Transplantation for Hepatocellular Carcinoma[J]. Liver Transpl, 2018, 24(11): 1603-1611. [44] MAZZAFERRO V, REGALIA E, DOCI R, et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334(11): 693-699. [45] REN A, LI Z, CHENG P, et al.Systemic Immune-Inflammation Index Is a Prognostic Predictor in Patients with Intrahepatic Cholangiocarcinoma Undergoing Liver Transplantation[J]. Mediators Inflamm, 2021, 2021: 6656996. [46] ONODERA T, GOSEKI N, KOSAKI G.[Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients][J]. Nihon Geka Gakkai Zasshi, 1984, 85(9): 1001-1005. [47] ALVARES-DA-SILVA M R, REVERBEL DA SILVEIRA T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients[J]. Nutrition, 2005, 21(2): 113-117. [48] KAWAMURA N, NAKAJIMA H, TAKASHI S I.Administration of granulated BCAA and quality of life[J]. Hepatol Res, 2004, 30s: 42-45. [49] JIANG N, DENG J Y, DING X W, et al.Prognostic nutritional index predicts postoperative complications and long-term outcomes of gastric cancer[J]. World J Gastroenterol, 2014, 20(30): 10537-10544. [50] GENG Y, QI Q, SUN M, et al.Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer[J]. Eur J Surg Oncol, 2015, 41(11): 1508-1514. [51] OKAMURA Y, SUGIURA T, ITO T, et al.The optimal cut-off value of the preoperative prognostic nutritional index for the survival differs according to the TNM stage in hepatocellular carcinoma[J]. Surg Today, 2017, 47(8): 986-993. [52] AINO H, SUMIE S, NIIZEKI T, et al.The systemic inflammatory response as a prognostic factor for advanced hepatocellular carcinoma with extrahepatic metastasis[J]. Mol Clin Oncol, 2016, 5(1): 83-88. [53] WANG D, DUAN L, TU Z, et al.The Glasgow Prognostic Score Predicts Response to Chemotherapy in Patients with Metastatic Breast Cancer[J]. Chemotherapy, 2016, 61(4): 217-222. [54] KNIGHT B C, KAUSAR A, MANU M, et al.Evaluation of surgical outcome scores according to ISGPS definitions in patients undergoing pancreatic resection[J]. Dig Surg, 2010, 27(5): 367-374. [55] POLTERAUER S, GRIMM C, SEEBACHER V, et al.The inflammation-based Glasgow Prognostic Score predicts survival in patients with cervical cancer[J]. Int J Gynecol Cancer, 2010, 20(6): 1052-1057. [56] ABE T, TASHIRO H, HATTORI M, et al.Prediction of long-term survival by using the Glasgow Prognostic Score in patients with hepatocellular carcinoma after liver transplantation[J]. Hepatol Res, 2016, 46(7): 622-633. [57] KALTENBORN A, SCHREM H, REICHERT B, et al.The Glasgow Prognostic Score and its variants predict mortality in living donor but not in deceased donor liver transplantation for hepatocellular carcinoma: A double-center validation study[J]. Hepatol Res, 2017, 47(8): 783-792. [58] AGALAR C, EGELI T, UNEK T, et al.The Predictive Ability of the Glasgow Prognostic Score and Variants in Both Deceased Donor and Living Donor Liver Transplantation for Hepatocellular Cancer[J]. Transplant Proc, 2019, 51(4): 1134-1138. |
[1] | He Qiang, Zhou Lin. To establish a comprehensive prevention and treatment system based on rapamycin for cancer recurrence after liver transplantation [J]. Electronic Journal of Liver Tumor, 2021, 8(3): 1-7. |
[2] | Jiang Tao, Pan Fei, Chen Qing, Huang Jincan, He Qiang, Lang Ren. Clinical study on individualized medication of tacrolimus after liver transplantation guided by CYP3A5 gene polymorphism for hepatocellular carcinoma [J]. Electronic Journal of Liver Tumor, 2021, 8(3): 8-11. |
[3] | Xie Yan, Zhang Weiqi, Sun Jisan, Jiang Wentao. Comparison of comprehensive therapy and local therapy of recurrence after liver transplantation in patients with hepatocellular carcinoma beyond Milan criteria [J]. Electronic Journal of Liver Tumor, 2021, 8(3): 12-16. |
[4] | Zhou Lin, Wang Jing, Zhao Yang, Li Han, Du Guosheng, Shi Xianjie, He Qiang, Lang Ren. HIF-1α is a negative prognostic indicator associated with poor survival benefits of HCC patients [J]. Electronic Journal of Liver Tumor, 2021, 8(3): 17-25. |
[5] | Lyu Shaocheng, Lang Ren. Progress on liver transplantation in the treatment of liver metastases [J]. Electronic Journal of Liver Tumor, 2021, 8(3): 26-29. |
[6] | Xiong Jun, Wan Chidan. Immune checkpoint inhibitors in liver transplantation patients with hepatocellular carcinoma [J]. Electronic Journal of Liver Tumor, 2021, 8(3): 30-34. |
[7] | Lin Xin, Xiao Min, Li Qiyong. How to evaluate donors' liver volume: a review of researches [J]. Electronic Journal of Liver Tumor, 2021, 8(3): 41-45. |
[8] | Zheng Yuanwen, Liu Jun. Discussion on the whole course management of preventing recurrence of liver cancer after liver transplantation [J]. Electronic Journal of Liver Tumor, 2021, 8(3): 46-50. |
[9] | Fu Zuojun, Liu Guisheng. Research progress of serum markers for early diagnosis of hepatocellular carcinoma [J]. Electronic Journal of Liver Tumor, 2021, 8(3): 51-54. |
[10] | Wu Jie, Gao Fei, Zhang Xuesong, Wang Kuiyang, Sui Chengxu, Zhang Liang, Yao Yuanfang, Song Lei. The significance of cystatin SN expression in hepatocellular carcinoma [J]. Electronic Journal of Liver Tumor, 2021, 8(2): 33-38. |
[11] | Huang Xiaozhun, Wang Chunling, Huang Zhangkan, Xu Lin, Zhang Renjie, Bi Xinyu, Che Xu, Zhao Jianjun. Research progress on the influence of margin width on the prognosis of hepatocellular carcinoma [J]. Electronic Journal of Liver Tumor, 2021, 8(2): 39-42. |
[12] | Huang Guirong, Wu Deping, Chen Fangpeng, Han Shanshan. NRS-2002 and CONUT scores and prognostic analysis of patients with advanced hepatocellular carcinoma and Nomogram model construction [J]. Electronic Journal of Liver Tumor, 2021, 8(2): 62-68. |
[13] | Shang Fuchao, Wang Menglong. Current conditions and developments for radical therapies of small hepatocellular carcinoma [J]. Electronic Journal of Liver Tumor, 2020, 7(4): 9-12. |
[14] | Peng Xuenan, Zhou Aiping. Research progress in immunotherapy and biomarkers for hepatocellular carcinoma [J]. Electronic Journal of Liver Tumor, 2020, 7(4): 17-22. |
[15] | Ge Dazhuang, Bi Xinyu, Zhao Hong, Li Zhiyu, Zhang Yefan, Luo Zhiwen, Wei Zhewen, Chen Qichen, Li Xingchen, Cai Jianqiang. Primary hepatobiliary neuroendocrine tumors: a case review and literature review [J]. Electronic Journal of Liver Tumor, 2020, 7(4): 23-28. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||